Trial Profile
Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- Acronyms PRODIGE18
- Sponsors UNICANCER
- 13 Nov 2020 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Results of final analysis presented at the 42nd European Society for Medical Oncology Congress
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.